miR-146a and miR-155 expression in PBMCs from patients with Sjögren's syndrome

Journal of Oral Pathology and Medicine

Volumn 43, Issue 10, 2014, Pages 792-797

  Shi, Huan ^a   Zheng, Ling yan ^a   Zhang, Ping ^a   Yu, Chuang qi ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Disease activity; MiR 146a; MiR 155; Sj gren's syndrome; VAS

Indexed keywords

MICRORNA 146A; MICRORNA 155; MICRORNA; MIRN146 MICRORNA, HUMAN; MIRN155 MICRORNA, HUMAN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATIONAL STUDY; DRY EYE; FEMALE; HUMAN; MALE; PAROTID GLAND SWELLING; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SJOEGREN SYNDROME; SWELLING; VISUAL ANALOG SCALE; XEROSTOMIA; BLOOD; CHEMISTRY; CLASSIFICATION; COMPARATIVE STUDY; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MIDDLE AGED; MONONUCLEAR CELL; PAROTITIS; XEROPHTHALMIA;

ADULT; FEMALE; GENE EXPRESSION REGULATION; HUMANS; LEUKOCYTES, MONONUCLEAR; MALE; MICRORNAS; MIDDLE AGED; PAROTITIS; SJOGREN'S SYNDROME; XEROPHTHALMIA; XEROSTOMIA;

EID: 84911379428     PISSN: 09042512     EISSN: 16000714     Source Type: Journal    
DOI: 10.1111/jop.12187     Document Type: Article

References (33)

1. Venables PJ. Management of patients presenting with Sjogren's syndrome. Best practice & research. Clin Rheumatol 2006; 20: 791-807.
2. Manthorpe R. Sjogren's syndrome criteria. Ann Rheum Dis 2002; 61: 482-4.
3. Vitali C, Bombardieri S, Jonsson R, et al. Classification criteria for Sjogren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002; 61: 554-8.
4. Bolstad AI, Jonsson R. Genetic aspects of Sjogren's syndrome. Arthritis Res 2002; 4: 353-9.
5. Hansen A, Lipsky PE, Dorner T. Immunopathogenesis of primary Sjogren's syndrome: implications for disease management and therapy. Curr Opin Rheumatol 2005; 17: 558-65.
6. Gottenberg JE, Cagnard N, Lucchesi C, et al. Activation of IFN pathways and plasmacytoid dendritic cell recruitment in target organs of primary Sjogren's syndrome. Proc Natl Acad Sci USA 2006; 103: 2770-5.
7. Fox RI. Sjögren's syndrome. Lancet 2005; 366: 321-31.
8. Fox RI, Stern M, Michelson P. Update in Sjogren syndrome. Curr Opin Rheumatol 2000; 12: 391-8.
9. Takei M, Shiraiwa H, Azuma T, et al. The possible etiopathogenic genes of Sjogren's syndrome. Autoimmun Rev 2005; 4: 479-84.
10. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004; 116: 281-97.
11. Yang M, Li Y, Padgett RW. MicroRNAs: Small regulators with a big impact. Cytokine Growth Factor Rev 2005; 16: 387-93.
12. Pauley KM, Cha S, Chan EK. MicroRNA in autoimmunity and autoimmune diseases. J Autoimmun 2009; 32: 189-94.
13. Lu LF, Liston A. MicroRNA in the immune system, microRNA as an immune system. Immunology 2009; 127: 291-8.
14. Liang TJ, Qin CY. The emerging role of microRNAs in immune cell development and differentiation. APMIS: acta pathologica, microbiologica, et immunologica. Scandinavica 2009; 117: 635-43.
15. Taganov KD, Boldin MP, Chang KJ, et al. NF-kappaB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proc Natl Acad Sci USA 2006; 103: 12481-6.
16. Bhaumik D, Scott GK, Schokrpur S, et al. Expression of microRNA-146 suppresses NF-kappaB activity with reduction of metastatic potential in breast cancer cells. Oncogene 2008; 27: 5643-7.
17. Pauley KM, Satoh M, Chan AL, et al. Upregulated miR-146a expression in peripheral blood mononuclear cells from rheumatoid arthritis patients. Arthritis Res Ther 2008; 10: R101.
18. Tang Y, Luo X, Cui H, et al. MicroRNA-146A contributes to abnormal activation of the type I interferon pathway in human lupus by targeting the key signaling proteins. Arthritis Rheum 2009; 60: 1065-75.
19. Rodriguez A, Vigorito E, Clare S, et al. Requirement of bic/microRNA-155 for normal immune function. Science 2007; 316: 608-11.
20. Lu LF, Thai TH, Calado DP, et al. Foxp3-dependent microRNA155 confers competitive fitness to regulatory T cells by targeting SOCS1 protein. Immunity 2009; 30: 80-91.
21. Ceppi M, Pereira PM, Dunand-Sauthier I, et al. MicroRNA-155 modulates the interleukin-1 signaling pathway in activated human monocyte-derived dendritic cells. Proc Natl Acad Sci USA 2009; 106: 2735-40.
22. Vigorito E, Perks KL, Abreu-Goodger C, et al. microRNA-155 regulates the generation of immunoglobulin class-switched plasma cells. Immunity 2007; 27: 847-59.
23. Wang G, Tam LS, Kwan BC, et al. Expression of miR-146a and miR-155 in the urinary sediment of systemic lupus erythematosus. Clin Rheumatol 2012; 31: 435-40.
24. Stanczyk J, Pedrioli DM, Brentano F, et al. Altered expression of MicroRNA in synovial fibroblasts and synovial tissue in rheumatoid arthritis. Arthritis Rheum 2008; 58: 1001-9.
25. Nakasa T, Miyaki S, Okubo A, et al. Expression of microRNA-146 in rheumatoid arthritis synovial tissue. Arthritis Rheum 2008; 58: 1284-92.
26. Boldin MP, Taganov KD, Rao DS, et al. miR-146a is a significant brake on autoimmunity, myeloproliferation, and cancer in mice. J Exp Med 2011; 208: 1189-201.
27. Zhao JL, Rao DS, Boldin MP, et al. NF-kappaB dysregulation in microRNA-146a-deficient mice drives the development of myeloid malignancies. Proc Natl Acad Sci USA 2011; 108: 9184-9.
28. Luo X, Yang W, Ye DQ, et al. A functional variant in microRNA-146a promoter modulates its expression and confers disease risk for systemic lupus erythematosus. PLoS Genet 2011; 7: e1002128.
29. Zilahi E, Tarr T, Papp G, et al. Increased microRNA-146a/b, TRAF6 gene and decreased IRAK1 gene expressions in the peripheral mononuclear cells of patients with Sjogren's syndrome. Immunol Lett 2012; 141: 165-8.
30. Murata K, Yoshitomi H, Tanida S, et al. Plasma and synovial fluid microRNAs as potential biomarkers of rheumatoid arthritis and osteoarthritis. Arthritis Res Ther 2010; 12: R86.
31. Costinean S, Sandhu SK, Pedersen IM, et al. Src homology 2 domain-containing inositol-5-phosphatase and CCAAT enhancer-binding protein beta are targeted by miR-155 in B cells of Emicro-MiR-155 transgenic mice. Blood 2009; 114: 1374-82.
32. Zhou Q, Xiao X, Wang C, et al. Decreased microRNA-155 expression in ocular Behcet's disease but not in Vogt Koyanagi Harada syndrome. Invest Ophthalmol Vis Sci 2012; 53: 5665-74.
33. Pauley KM, Stewart CM, Gauna AE, et al. Altered miR-146a expression in Sjogren's syndrome and its functional role in innate immunity. Eur J Immunol 2011; 41: 2029-39.